Scholarlink

Purpose <p>To investigate the efficacy of intravitreal anti-VEGF agents in the treatment of Irvine-Gass syndrome (IGS).</p> Methods <p>Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.</p> Results <p>Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.</p> Conclusion <p>Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of anti-VEGF therapy for Irvine-Gass syndrome: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年1月20日

查看全文
  • Daniel Balsby,
  • Andreas Arnold-Vangsted,
  • Emil Alexander Rosenørn,
  • Nathalie Skovgaard Eriksen,
  • Hassan Javed Ahmed,
  • Therese Grønhøj Krarup,
  • Oliver Niels Klefter,
  • Javad Nouri Hajari,
  • Yousif Subhi,
  • Miklos Schneider

摘要

Purpose

To investigate the efficacy of intravitreal anti-VEGF agents in the treatment of Irvine-Gass syndrome (IGS).

Methods

Systematic review with meta-analysis. The primary outcome was the percentage with resolution of cystoid macular edema (CME). Secondary outcomes were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to time of follow-up. A meta-analysis was conducted on changes in BCVA and CMT from baseline to a 6-month follow-up visit.

Results

Seven retrospective studies and one randomized, sham-controlled, multicenter study provided data on a total of 343 eyes of 334 patients. The primary outcome was reported too heterogeneously to allow for meta-analysis, but three studies reported resolution of CME during follow-up in 66.4% to 100% of eyes treated. At 6 months after treatment initiation, the mean improvement in BCVA was 0.65 (95%CI: -0.83; -0.47) logMAR, and the mean decrease in CMT was 290.41 (95%CI: -351.33; -229.54) µm.

Conclusion

Current literature suggests potential benefits of intravitreal anti-VEGF in treating IGS. However, its superiority over placebo remains uncertain, suggesting the need for randomized, placebo-controlled trials.